Asset Details
Do you wish to reserve the book?
Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
Do you wish to request the book?
Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
2013
Overview
The use of finasteride to prevent prostate cancer reduced the risk of low-grade tumors by 43%, as compared with placebo. High-grade tumors were more common in the finasteride group, but long-term follow-up did not show a significant between-group difference in survival.
With the advent of prostate-specific antigen (PSA) testing in the late 1980s, the rate of diagnosis of prostate cancer rose dramatically. Currently, a man in the United States has a 16.5% lifetime risk of receiving a diagnosis of prostate cancer.
1
The timing and magnitude of the 44% reduction in prostate-cancer mortality after the widespread adoption of PSA testing suggest that both screening and treatment improvements have contributed to this decline.
2
Unfortunately, treatments for prostate cancer (radiation and surgery) are associated with a substantial risk of side effects, including sexual, urinary, and bowel complications, that can dramatically affect quality of life. . . .
Publisher
Massachusetts Medical Society
Subject
5-alpha Reductase Inhibitors - therapeutic use
/ Biological and medical sciences
/ Biopsy
/ Finasteride - therapeutic use
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Male
/ Men
/ Nephrology. Urinary tract diseases
/ Prostatic Neoplasms - epidemiology
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - pathology
/ Prostatic Neoplasms - prevention & control
/ Risk
/ Survival
/ Tumors
